Short Communication

Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques

Gregory Q. Del Prete, Jeremy Smedley, Rhonda MacAllister, Gregg S. Jones, Bei Li, Jillian Hattersley, Jim Zheng, Michael Piatak, Brandon F. Keele, Joseph Hesselgesser, Romas Geleziunas, Jeffrey D. Lifson

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The use of nonhuman primate (NHP) models to study persistent residual virus and viral eradication strategies in combination antiretroviral therapy (cART)-treated individuals requires regimens that effectively suppress SIV replication to clinically relevant levels in macaques. We developed and evaluated two novel cART regimens in SIVmac239-infected rhesus macaques: (1) a "triple regimen" containing the nucleo(s/t)ide reverse transcriptase inhibitors emtricitabine (FTC) and tenofovir disoproxil fumarate [TDF, prodrug of tenofovir (TFV, PMPA)] with the integrase strand transfer inhibitor dolutegravir (DTG) (n = 3), or (2) a "quad regimen" containing the same three drugs plus the protease inhibitor darunavir (DRV) (n = 3), with each regimen coformulated for convenient administration by a single daily subcutaneous injection. Plasma drug concentrations were consistent across animals within the triple and quad regimen-treated groups, although DTG levels were lower in the quad regimen animals. Time to achieve plasma viral loads stably

Original languageEnglish (US)
Pages (from-to)163-168
Number of pages6
JournalAIDS Research and Human Retroviruses
Volume32
Issue number2
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Tenofovir
Simian Immunodeficiency Virus
Macaca mulatta
Communication
Injections
Integrases
Reverse Transcriptase Inhibitors
Prodrugs
Macaca
Subcutaneous Injections
Protease Inhibitors
Viral Load
Pharmaceutical Preparations
Primates
Therapeutics
Viruses
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
dolutegravir

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Short Communication : Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques. / Del Prete, Gregory Q.; Smedley, Jeremy; MacAllister, Rhonda; Jones, Gregg S.; Li, Bei; Hattersley, Jillian; Zheng, Jim; Piatak, Michael; Keele, Brandon F.; Hesselgesser, Joseph; Geleziunas, Romas; Lifson, Jeffrey D.

In: AIDS Research and Human Retroviruses, Vol. 32, No. 2, 01.02.2016, p. 163-168.

Research output: Contribution to journalArticle

Del Prete, Gregory Q. ; Smedley, Jeremy ; MacAllister, Rhonda ; Jones, Gregg S. ; Li, Bei ; Hattersley, Jillian ; Zheng, Jim ; Piatak, Michael ; Keele, Brandon F. ; Hesselgesser, Joseph ; Geleziunas, Romas ; Lifson, Jeffrey D. / Short Communication : Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques. In: AIDS Research and Human Retroviruses. 2016 ; Vol. 32, No. 2. pp. 163-168.
@article{7804a5b340e84734b732b21d4e623073,
title = "Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques",
abstract = "The use of nonhuman primate (NHP) models to study persistent residual virus and viral eradication strategies in combination antiretroviral therapy (cART)-treated individuals requires regimens that effectively suppress SIV replication to clinically relevant levels in macaques. We developed and evaluated two novel cART regimens in SIVmac239-infected rhesus macaques: (1) a {"}triple regimen{"} containing the nucleo(s/t)ide reverse transcriptase inhibitors emtricitabine (FTC) and tenofovir disoproxil fumarate [TDF, prodrug of tenofovir (TFV, PMPA)] with the integrase strand transfer inhibitor dolutegravir (DTG) (n = 3), or (2) a {"}quad regimen{"} containing the same three drugs plus the protease inhibitor darunavir (DRV) (n = 3), with each regimen coformulated for convenient administration by a single daily subcutaneous injection. Plasma drug concentrations were consistent across animals within the triple and quad regimen-treated groups, although DTG levels were lower in the quad regimen animals. Time to achieve plasma viral loads stably",
author = "{Del Prete}, {Gregory Q.} and Jeremy Smedley and Rhonda MacAllister and Jones, {Gregg S.} and Bei Li and Jillian Hattersley and Jim Zheng and Michael Piatak and Keele, {Brandon F.} and Joseph Hesselgesser and Romas Geleziunas and Lifson, {Jeffrey D.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1089/aid.2015.0130",
language = "English (US)",
volume = "32",
pages = "163--168",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Short Communication

T2 - Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques

AU - Del Prete, Gregory Q.

AU - Smedley, Jeremy

AU - MacAllister, Rhonda

AU - Jones, Gregg S.

AU - Li, Bei

AU - Hattersley, Jillian

AU - Zheng, Jim

AU - Piatak, Michael

AU - Keele, Brandon F.

AU - Hesselgesser, Joseph

AU - Geleziunas, Romas

AU - Lifson, Jeffrey D.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The use of nonhuman primate (NHP) models to study persistent residual virus and viral eradication strategies in combination antiretroviral therapy (cART)-treated individuals requires regimens that effectively suppress SIV replication to clinically relevant levels in macaques. We developed and evaluated two novel cART regimens in SIVmac239-infected rhesus macaques: (1) a "triple regimen" containing the nucleo(s/t)ide reverse transcriptase inhibitors emtricitabine (FTC) and tenofovir disoproxil fumarate [TDF, prodrug of tenofovir (TFV, PMPA)] with the integrase strand transfer inhibitor dolutegravir (DTG) (n = 3), or (2) a "quad regimen" containing the same three drugs plus the protease inhibitor darunavir (DRV) (n = 3), with each regimen coformulated for convenient administration by a single daily subcutaneous injection. Plasma drug concentrations were consistent across animals within the triple and quad regimen-treated groups, although DTG levels were lower in the quad regimen animals. Time to achieve plasma viral loads stably

AB - The use of nonhuman primate (NHP) models to study persistent residual virus and viral eradication strategies in combination antiretroviral therapy (cART)-treated individuals requires regimens that effectively suppress SIV replication to clinically relevant levels in macaques. We developed and evaluated two novel cART regimens in SIVmac239-infected rhesus macaques: (1) a "triple regimen" containing the nucleo(s/t)ide reverse transcriptase inhibitors emtricitabine (FTC) and tenofovir disoproxil fumarate [TDF, prodrug of tenofovir (TFV, PMPA)] with the integrase strand transfer inhibitor dolutegravir (DTG) (n = 3), or (2) a "quad regimen" containing the same three drugs plus the protease inhibitor darunavir (DRV) (n = 3), with each regimen coformulated for convenient administration by a single daily subcutaneous injection. Plasma drug concentrations were consistent across animals within the triple and quad regimen-treated groups, although DTG levels were lower in the quad regimen animals. Time to achieve plasma viral loads stably

UR - http://www.scopus.com/inward/record.url?scp=84958974351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958974351&partnerID=8YFLogxK

U2 - 10.1089/aid.2015.0130

DO - 10.1089/aid.2015.0130

M3 - Article

VL - 32

SP - 163

EP - 168

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 2

ER -